Literature DB >> 19286997

Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Robert E Throm1, Annastasia A Ouma, Sheng Zhou, Anantharaman Chandrasekaran, Timothy Lockey, Michael Greene, Suk See De Ravin, Morvarid Moayeri, Harry L Malech, Brian P Sorrentino, John T Gray.   

Abstract

Retroviral vectors containing internal promoters, chromatin insulators, and self-inactivating (SIN) long terminal repeats (LTRs) may have significantly reduced genotoxicity relative to the conventional retroviral vectors used in recent, otherwise successful clinical trials. Large-scale production of such vectors is problematic, however, as the introduction of SIN vectors into packaging cells cannot be accomplished with the traditional method of viral transduction. We have derived a set of packaging cell lines for HIV-based lentiviral vectors and developed a novel concatemeric array transfection technique for the introduction of SIN vector genomes devoid of enhancer and promoter sequences in the LTR. We used this method to derive a producer cell clone for a SIN lentiviral vector expressing green fluorescent protein, which when grown in a bioreactor generated more than 20 L of supernatant with titers above 10(7) transducing units (TU) per milliliter. Further refinement of our technique enabled the rapid generation of whole populations of stably transformed cells that produced similar titers. Finally, we describe the construction of an insulated, SIN lentiviral vector encoding the human interleukin 2 receptor common gamma chain (IL2RG) gene and the efficient derivation of cloned producer cells that generate supernatants with titers greater than 5 x 10(7) TU/mL and that are suitable for use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286997      PMCID: PMC2686181          DOI: 10.1182/blood-2008-11-191049

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy.

Authors:  E Vigna; L Naldini
Journal:  J Gene Med       Date:  2000 Sep-Oct       Impact factor: 4.565

2.  Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood.

Authors:  Hideki Hanawa; Patrick F Kelly; Amit C Nathwani; Derek A Persons; Jody A Vandergriff; Phillip Hargrove; Elio F Vanin; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

3.  Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors.

Authors:  S Sparacio; T Pfeiffer; H Schaal; V Bosch
Journal:  Mol Ther       Date:  2001-04       Impact factor: 11.454

4.  Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors.

Authors:  K Xu; H Ma; T J McCown; I M Verma; T Kafri
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

5.  Continuous high-titer HIV-1 vector production.

Authors:  Yasuhiro Ikeda; Yasuhiro Takeuchi; Francisco Martin; Francois-Loic Cosset; Kyriacos Mitrophanous; Mary Collins
Journal:  Nat Biotechnol       Date:  2003-04-07       Impact factor: 54.908

6.  An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.

Authors:  A L Pacchia; M E Adelson; M Kaul; Y Ron; J P Dougherty
Journal:  Virology       Date:  2001-03-30       Impact factor: 3.616

7.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

8.  Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo.

Authors:  Z Y Chen; C Y He; L Meuse; M A Kay
Journal:  Gene Ther       Date:  2004-05       Impact factor: 5.250

9.  A new-generation stable inducible packaging cell line for lentiviral vectors.

Authors:  D Farson; R Witt; R McGuinness; T Dull; M Kelly; J Song; R Radeke; A Bukovsky; A Consiglio; L Naldini
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

10.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

View more
  53 in total

1.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

2.  Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

Authors:  Yoon-Sang Kim; Matthew M Wielgosz; Phillip Hargrove; Steven Kepes; John Gray; Derek A Persons; Arthur W Nienhuis
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

Review 3.  Chronic granulomatous disease: lessons from a rare disorder.

Authors:  Brahm H Segal; Paul Veys; Harry Malech; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

Review 4.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

Review 6.  Transplantation immunology: solid organ and bone marrow.

Authors:  Javier Chinen; Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

7.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

8.  A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells.

Authors:  Paul D Bryson; Chupei Zhang; Chi-Lin Lee; Pin Wang
Journal:  J Vis Exp       Date:  2013-06-19       Impact factor: 1.355

Review 9.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

Review 10.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.